Blood Transfusion, All-Cause Mortality and Hospitalization Period in COVID-19 Patients: Machine Learning Analysis of National Health Insurance Claims Data
Abstract
:1. Introduction
2. Materials and Methods
2.1. Participants and Variables
2.2. Analysis
2.3. Ethics Statement
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sharma, A.; Tiwari, S.; Deb, M.K.; Marty, J.L. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): A global pandemic and treatment strategies. Int. J. Antimicrob. Agents 2020, 56, 106054. [Google Scholar] [CrossRef]
- Chauhan, S. Comprehensive review of coronavirus disease 2019 (COVID-19). Biomed. J. 2020, 43, 334–340. [Google Scholar] [CrossRef]
- Lai, C.C.; Shih, T.P.; Ko, W.C.; Tang, H.J.; Hsueh, P.R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents 2020, 55, 105924. [Google Scholar] [CrossRef]
- Rapp, J.L.; Lieberman-Cribbin, W.; Tuminello, S.; Taioli, E. Male sex, severe obesity, older age, and chronic kidney disease are associated with COVID-19 severity and mortality in New York City. Chest 2021, 159, 112–115. [Google Scholar] [CrossRef]
- Poly, T.N.; Islam, M.M.; Yang, H.C.; Lin, M.C.; Jian, W.-S.; Hsu, M.-H.; Li, Y.-C.J. Obesity and mortality among patients diagnosed with COVID-19: A systematic review and meta-analysis. Front. Med. 2021, 8, 620044. [Google Scholar] [CrossRef] [PubMed]
- Bellmann-Weiler, R.; Lanser, L.; Barket, R.; Rangger, L.; Schapfl, A.; Schaber, M.; Fritsche, G.; Wöll, E.; Weiss, G. Prevalence and predictive value of anemia and dysregulated iron homeostasis in patients with COVID-19 infection. J. Clin. Med. 2020, 9, 2429. [Google Scholar] [CrossRef] [PubMed]
- Faghih, D.M.; Somi, M.H.; Sadeghi, M.E.; Abbasalizad, F.M.; Nikniaz, Z. Anemia predicts poor outcomes of COVID-19 in hospitalized patients: A prospective study in Iran. BMC Infect. Dis. 2021, 21, 170. [Google Scholar]
- Oh, S.M.; Skendelas, J.P.; Macdonald, E.; Bergamini, M.; Goel, S.; Choi, J.; Segal, K.R.; Vivek, K.; Nair, S.; Leff, J. On-admission anemia predicts mortality in COVID-19 patients: A single center, retrospective cohort study. Am. J. Emerg. Med. 2021, 48, 140–147. [Google Scholar] [CrossRef] [PubMed]
- Tao, Z.; Xu, J.; Chen, W.; Yang, Z.; Xu, X.; Liu, L.; Chen, R.; Xie, J.; Liu, M.; Wu, J.; et al. Anemia is associated with severe illness in COVID-19: A retrospective cohort study. J. Med. Virol. 2021, 93, 1478–1488. [Google Scholar] [CrossRef] [PubMed]
- Young, B.E.; Ong, S.W.X.; Kalimuddin, S.; Low, J.G.; Tan, S.Y.; Loh, J.; Ng, O.T.; Marimuthu, K.; Ang, L.W.; Mak, T.M.; et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020, 323, 1488–1494. [Google Scholar] [CrossRef] [Green Version]
- Cecconi, M.; Piovani, D.; Brunetta, E.; Aghemo, A.; Greco, M.; Ciccarelli, M.; Angelini, C.; Voza, A.; Omodei, P.; Vespa, E.; et al. Early predictors of clinical deterioration in a cohort of 239 patients hospitalized for COVID-19 infection in Lombardy, Italy. J. Clin. Med. 2020, 9, 1548. [Google Scholar] [CrossRef]
- Stanworth, S.J.; New, H.V.; Apelseth, T.O.; Brunskill, S.; Cardigan, R.; Doree, C.; Germain, M.; Goldman, M.; Massey, E.; Prati, D.; et al. Effects of the COVID-19 pandemic on supply and use of blood for transfusion. Lancet Haematol. 2020, 7, e756–e764. [Google Scholar] [CrossRef]
- Al Mahmasani, L.; Hodroj, M.H.; Finianos, A.; Taher, A. COVID-19 pandemic and transfusion medicine: The worldwide challenge and its implications. Ann. Hematol. 2021, 100, 1115–1122. [Google Scholar] [CrossRef]
- Barriteau, C.M.; Bochey, P.; Lindholm, P.F.; Hartman, K.; Sumugod, R.; Ramsey, G. Blood transfusion utilization in hospitalized COVID-19 patients. Transfusion. 2020, 60, 1919–1923. [Google Scholar] [CrossRef]
- Grandone, E.; Pesavento, R.; Tiscia, G.; De Laurenzo, A.; Ceccato, D.; Sartori, M.; Mirabella, L.; Cinnella, G.; Mastroianno, M.; Dalfino, L.; et al. Mortality and transfusion requirements in COVID-19 hospitalized Italian patients according to severity of the disease. J. Clin. Med. 2021, 10, 242. [Google Scholar] [CrossRef]
- Charlson, M.E.; Pompei, P.; Ales, K.L.; MacKenzie, C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J. Chronic Dis. 1987, 40, 373–383. [Google Scholar] [CrossRef]
- Myttenaere, A.D.; Golden, B.; Grand, B.L.; Rossi, F. Mean Absolute Percentage Error for regression models. Neurocomputing 2016, 192, 38–48. [Google Scholar] [CrossRef] [Green Version]
- Fan, B.E.; Ong, K.H.; Chan, S.S.W.; Young, B.E.; Chong, V.C.L.; Chen, S.P.C.; Lim, S.P.; Lim, G.P.; Kuperan, P. Blood and blood product use during COVID-19 infection. Am. J. Hematol. 2020, 95, E158–E160. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rim, J.H.; Lee, S.A.; Han, C.H.; Yoo, J. Transfusion demand in COVID-19 patients from the Korean population: A nationwide study in South Korea. Br. J. Haematol. 2020, 190, e323–e326. [Google Scholar] [CrossRef]
- Cho, S.I.; Yoon, S.; Lee, H.J. Impact of comorbidity burden on mortality in patients with COVID-19 using the Korean health insurance database. Sci. Rep. 2021, 11, 6375. [Google Scholar] [CrossRef] [PubMed]
- Tuty Kuswardhani, R.A.; Henrina, J.; Pranata, R.; Anthonius, L.M.; Lawrensia, S.; Suastika, K. Charlson comorbidity index and a composite of poor outcomes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Metab. Syndr. 2020, 14, 2103–2109. [Google Scholar] [CrossRef] [PubMed]
- Varol, Y.; Hakoglu, B.; Kadri Cirak, A.; Polat, G.; Komurcuoglu, B.; Akkol, B.; Atasoy, C.; Bayramic, E.; Balci, G.; Ataman, S.; et al. The impact of Charlson comorbidity index on mortality from SARS-CoV-2 virus infection and A novel COVID-19 mortality index: CoLACD. Int. J. Clin. Pract. 2021, 75, e13858. [Google Scholar] [CrossRef]
- Han, J.; Micheline, K. Data Mining: Concepts and Techniques, 2nd ed.; Elsevier: San Francisco, CA, USA, 2006. [Google Scholar]
ALL (n = 7943) | Group 1 (High Index, n = 3056) | Group 2 (Low Index, n = 4887) | |||||||
---|---|---|---|---|---|---|---|---|---|
Variables | No (n) | Yes (n) | Yes (%) | No (n) | Yes (n) | Yes (%) | No (n) | Yes (n) | Yes (%) |
Anemia | 7422 | 521 | 6.56 | 2729 | 327 | 10.70 | 4693 | 194 | 3.97 |
Antiplatelet agents | 6984 | 959 | 12.07 | 2177 | 879 | 28.76 | 4807 | 80 | 1.64 |
Congestive Heart Failure | 7714 | 229 | 2.88 | 2856 | 200 | 6.54 | 4858 | 29 | 0.59 |
Chronic Kidney Disease | 7872 | 71 | 0.89 | 2988 | 68 | 2.23 | 4884 | 3 | 0.06 |
Chronic Obstructive Pulmonary Disease | 7289 | 654 | 8.23 | 2560 | 496 | 16.23 | 4729 | 158 | 3.23 |
Cryoprecipitate | 7939 | 4 | 0.05 | 3053 | 3 | 0.10 | 4886 | 1 | 0.02 |
Connective Tissue Disease | 7879 | 64 | 0.81 | 3004 | 52 | 1.70 | 4875 | 12 | 0.25 |
Cardiovascular Disease | 7539 | 404 | 5.09 | 2672 | 384 | 12.57 | 4867 | 20 | 0.41 |
Death | 7698 | 245 | 3.08 | 2815 | 241 | 7.89 | 4883 | 4 | 0.08 |
Dementia | 7428 | 515 | 6.48 | 2549 | 507 | 16.59 | 4879 | 8 | 0.16 |
Diabetes Mellitus | 6724 | 1219 | 15.35 | 2007 | 1049 | 34.33 | 4717 | 170 | 3.48 |
Fresh Frozen Plasma | 7909 | 34 | 0.43 | 3027 | 29 | 0.95 | 4882 | 5 | 0.10 |
Hemiplegia | 7853 | 90 | 1.13 | 2969 | 87 | 2.85 | 4884 | 3 | 0.06 |
Iron | 7707 | 236 | 2.97 | 2894 | 162 | 5.30 | 4813 | 74 | 1.51 |
Leukemia | 7937 | 6 | 0.08 | 3052 | 4 | 0.13 | 4885 | 2 | 0.04 |
Liver Disease | 6549 | 1394 | 17.55 | 2056 | 1000 | 32.72 | 4493 | 394 | 8.06 |
Lymphoma | 7934 | 9 | 0.11 | 3049 | 7 | 0.23 | 4885 | 2 | 0.04 |
Myocardial Infarction | 7474 | 469 | 5.90 | 2693 | 363 | 11.88 | 4781 | 106 | 2.17 |
Platelet Transfusion | 7891 | 52 | 0.65 | 3010 | 46 | 1.51 | 4881 | 6 | 0.12 |
Peptic Ulcer Disease | 7109 | 834 | 10.50 | 2512 | 544 | 17.80 | 4597 | 290 | 5.93 |
Peripheral Vascular Disease | 7539 | 404 | 5.09 | 2689 | 367 | 12.01 | 4850 | 37 | 0.76 |
Red Blood Cell Transfusion | 7761 | 182 | 2.29 | 2888 | 168 | 5.50 | 4873 | 14 | 0.29 |
Gender | 3177 | 4766 | 60.00 | 1183 | 1873 | 61.29 | 1994 | 2893 | 59.20 |
Solid Tumor | 7656 | 287 | 3.61 | 2795 | 261 | 8.54 | 4861 | 26 | 0.53 |
Thrombocytopenia | 7916 | 27 | 0.34 | 3037 | 19 | 0.62 | 4879 | 8 | 0.16 |
Tranexamic acid | 7835 | 108 | 1.36 | 2970 | 86 | 2.81 | 4865 | 22 | 0.45 |
All | Min | Q1 | Median | Mean | Q3 | Max |
---|---|---|---|---|---|---|
Age | 0 | 2 | 4 | 4.17 | 6 | 8 |
Charlson Comorbidity Index | 0 | 0 | 1 | 1.82 | 3 | 12 |
Hospitalization Period | 2 | 21 | 33 | 48.67 | 53 | 329 |
Insurance Fee | 0 | 3 | 10 | 10.00 | 16 | 20 |
Group 1 (High Index) | ||||||
Age | 3 | 5 | 6 | 6.16 | 7 | 8 |
Charlson Comorbidity Index | 2 | 3 | 4 | 4.07 | 5 | 12 |
Hospitalization Period | 2 | 33 | 52 | 74.52 | 90 | 329 |
Insurance Fee | 0 | 2 | 10 | 9.62 | 16 | 20 |
Group 2 (Low Index) | ||||||
Age | 0 | 2 | 3 | 2.93 | 4 | 5 |
Charlson Comorbidity Index | 0 | 0 | 0 | 0.42 | 1 | 3 |
Hospitalization Period | 2 | 19 | 27 | 32.51 | 39 | 270 |
Insurance Fee | 0 | 4 | 11 | 10.24 | 16 | 20 |
No. | Proportion (%) | |||
---|---|---|---|---|
All | Group 1 (High Index) | 3056 | 38.5 | |
Group 2 (Low Index) | 4887 | 61.5 | ||
Red Blood Cell | Group 1 | Non-transfused | 2888 | 94.5 |
Transfused | 168 | 5.5 | ||
Group 2 | Non-transfused | 4873 | 99.7 | |
Transfused | 14 | 0.3 | ||
Platelet | Group 1 | Non-transfused | 3010 | 98.5 |
Transfused | 46 | 1.5 | ||
Group 2 | Non-transfused | 4881 | 99.9 | |
Transfused | 6 | 0.1 | ||
Fresh Frozen Plasma | Group 1 | Non-transfused | 3027 | 99 |
Transfused | 29 | 1 | ||
Group 2 | Non-transfused | 4882 | 99.9 | |
Transfused | 5 | 0.1 | ||
Cryoprecipitate | Group 1 | Non-transfused | 3053 | 99.9 |
Transfused | 3 | 0.1 | ||
Group 2 | Non-transfused | 4886 | 99.9 | |
Transfused | 1 | 0.1 |
No. | Proportion (%) | |||
---|---|---|---|---|
All | Dead | 980 | 3.1 | |
Alive | 30791 | 96.9 | ||
Red Blood Cell | Dead | Non-transfused | 172 | 70.2 |
Transfused | 73 | 29.8 | ||
Alive | Non-transfused | 7589 | 98.6 | |
Transfused | 109 | 1.4 | ||
Platelet | Dead | Non-transfused | 217 | 11.4 |
Transfused | 28 | 88.6 | ||
Alive | Non-transfused | 7674 | 99.7 | |
Transfused | 24 | 0.3 | ||
Fresh Frozen Plasma | Dead | Non-transfused | 228 | 93.1 |
Transfused | 17 | 6.9 | ||
Alive | Non-transfused | 7681 | 99.8 | |
Transfused | 17 | 0.2 | ||
Cryoprecipitate | Dead | Non-transfused | 243 | 99.2 |
Transfused | 2 | 0.8 | ||
Alive | Non-transfused | 7696 | 99.9 | |
Transfused | 2 | 0.1 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lee, B.-H.; Lee, K.-S.; Kim, H.-I.; Jung, J.-S.; Shin, H.-J.; Park, J.-H.; Hong, S.-C.; Ahn, K.H. Blood Transfusion, All-Cause Mortality and Hospitalization Period in COVID-19 Patients: Machine Learning Analysis of National Health Insurance Claims Data. Diagnostics 2022, 12, 2970. https://doi.org/10.3390/diagnostics12122970
Lee B-H, Lee K-S, Kim H-I, Jung J-S, Shin H-J, Park J-H, Hong S-C, Ahn KH. Blood Transfusion, All-Cause Mortality and Hospitalization Period in COVID-19 Patients: Machine Learning Analysis of National Health Insurance Claims Data. Diagnostics. 2022; 12(12):2970. https://doi.org/10.3390/diagnostics12122970
Chicago/Turabian StyleLee, Byung-Hyun, Kwang-Sig Lee, Hae-In Kim, Jae-Seung Jung, Hyeon-Ju Shin, Jong-Hoon Park, Soon-Cheol Hong, and Ki Hoon Ahn. 2022. "Blood Transfusion, All-Cause Mortality and Hospitalization Period in COVID-19 Patients: Machine Learning Analysis of National Health Insurance Claims Data" Diagnostics 12, no. 12: 2970. https://doi.org/10.3390/diagnostics12122970